DA
Therapeutic Areas
iBio Pipeline
| Drug | Indication | Phase |
|---|---|---|
| IBIO-610 | Obesity and Cardiometabolic Disease | IND-Enabling |
| Myostatin x Activin A Bispecific | Obesity and Cardiometabolic Disease | Optimization |
| IBIO-600 | Obesity and Cardiometabolic Disease | IND-Enabling |
| Amylin Antibody | Obesity and Cardiometabolic Disease | Optimization |
| Target 4 Program | Obesity and Cardiometabolic Disease | Discovery |
Leadership Team at iBio
MB
Martin Brenner
Chief Executive Officer and Chief Scientific Officer
FD
Felipe Duran
Chief Financial Officer
MB
Marc Banjak
Chief Legal Officer
CC
Chip Clark
Chairman of the Board
AK
Alexandra Kropotova
Director
AP
António Parada
Director
ES
Eef Schimmelpennink
Director
GS
Gary Sender
Director